Atritech raises $22,000,000

Atritech, Inc., a clinical stage medical device company, announced today that it has completed a $22 million round of financing. Atritech’s WATCHMAN(R) device is designed to keep harmful sized blood clots from entering a patient’s blood stream, potentially causing a stroke. Patients with atrial fibrillation (a heart condition which causes the upper chambers of the heart to beat too rapidly) are at a significantly greater risk of having a stroke. Typically these patients require blood thinning medications to prevent these clots from forming in the heart.